Evidence map›Paper›PMID 26766040›Full record

ArticlePloS one2016

Hepatitis B Virus HBx Activates Notch Signaling via Delta-Like 4/Notch1 in Hepatocellular Carcinoma.

Pornrat Kongkavitoon, Pisit Tangkijvanich, Nattiya Hirankarn, Tanapat Palaga

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Short-chain fatty acids in cancer pathogenesis.Cancer metastasis reviews · 2023
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Notch signaling pathway in infectious diseases: role in the regulation of immune response.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Review
  13. Review
  14. Review
  15. When Viruses Cross Developmental Pathways.Frontiers in cell and developmental biology · 2021
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Pornrat KongkavitoonCenter of Excellence in Immunology and Immune-mediated Diseases, Chulalongkorn University, Bangkok, Thailand.
Pisit TangkijvanichResearch Unit of Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Nattiya HirankarnCenter of Excellence in Immunology and Immune-mediated Diseases, Chulalongkorn University, Bangkok, Thailand.
Tanapat PalagaCenter of Excellence in Immunology and Immune-mediated Diseases, Chulalongkorn University, Bangkok, Thailand.
Chulalongkorn University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis virus B (HBV) infection is one of the major causes of hepatocellular carcinomas (HCC). HBx protein encoded in HBV genome is one of the key viral factors leading to malignant transformation of infected cells. HBx functions by interfering with cellular functions, causing aberration in cellular behaviour and transformation. Notch signalling is a well-conserved pathway involved in cellular differentiation, cell survival and cell death operating in various types of cells. Aberration in the Notch signalling pathways is linked to various tumors, including HCC. The role of HBx on the Notch signalling in HCC, however, is still controversial. In this study, we reported that HBV genome-containing HCC cell line HepG2 (HepG2.2.15) expressed higher Notch1 and Delta-like 4 (Dll4), compared to the control HepG2 without HBV genome. This upregulation coincided with increased appearance of the cleavage of Notch1, indicating constitutively activated Notch signalling. Silencing of HBx specifically reduced the level of Dll4 and cleaved Notch1. The increase in Dll4 level was confirmed in clinical specimens of HCC lesion, in comparison with non-tumor lesions. Using specific signalling pathway inhibitors, we found that MEK1/2, PI3K/AKT and NF-κB pathways are critical for HBx-mediated Dll4 upregulation. Silencing of HBx clearly decreased the level of phosphorylation of Akt and Erk1/2. Upon silencing of Dll4 in HepG2.2.15, decreased cleaved Notch1, increased apoptosis and cell cycle arrest were observed, suggesting a critical role of HBx-Dll4-Notch1 axis in regulating cell survival in HCC. Furthermore, clonogenic assay confirmed the important role of Dll4 in regulating cell survival of HBV-genome containing HCC cell line. Taken together, we reported a link between HBx and the Notch signalling in HCC that affects cell survival of HCC, which can be a potential target for therapy.

Indexed as

Adaptor Proteins, Signal TransducingCalcium-Binding ProteinsCarcinoma, HepatocellularCells, CulturedHep G2 CellsHumansIntercellular Signaling Peptides and ProteinsLiver NeoplasmsReceptor, Notch1Signal TransductionTrans-ActivatorsViral Regulatory and Accessory ProteinsAdaptor Proteins, Signal TransducingCalcium-Binding ProteinsDLL4 protein, humanhepatitis B virus X proteinIntercellular Signaling Peptides and ProteinsReceptor, Notch1Trans-ActivatorsViral Regulatory and Accessory Proteins

Identifiers

PMID26766040
PMCPMC4713073
OpenAlexW2233614137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.